International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(13), С. 7377 - 7377
Опубликована: Июль 5, 2024
Gastric
cancer
is
the
fifth
most
common
disease
in
world
and
fourth
cause
of
death.
It
diagnosed
through
esophagogastroduodenoscopy
with
biopsy;
however,
there
are
limitations
finding
lesions
early
stages.
Recently,
research
has
been
actively
conducted
to
use
liquid
biopsy
diagnose
various
cancers,
including
gastric
cancer.
Various
substances
derived
from
reflected
blood.
By
analyzing
these
substances,
it
was
expected
that
not
only
presence
or
absence
but
also
type
can
be
diagnosed.
However,
amount
extremely
small,
even
have
variables
depending
on
characteristics
individual
To
overcome
these,
we
collected
methylated
DNA
fragments
using
MeDIP
compared
them
normal
plasma
characterize
tissue
patients'
plasma.
We
attempted
blood
As
a
result,
confirmed
consistency
between
approximately
41.2%
found
possibility
diagnosing
characterizing
SFR
5'end-motif
analysis.
World Journal of Gastrointestinal Oncology,
Год журнала:
2025,
Номер
17(4)
Опубликована: Март 24, 2025
A
recent
study
by
Long
et
al
used
a
predictive
model
to
explore
the
efficacy
of
radiomics
based
on
multiparametric
magnetic
resonance
imaging
in
predicting
metachronous
liver
metastasis
(MLM)
newly
diagnosed
rectal
cancer
(RC)
patients.
The
machine
learning
algorithms,
particularly
random
forest
(RFM),
appeared
well-matched
complex
nature
data.
capabilities
RFM,
as
evidenced
area
under
curve
0.919
training
cohort
and
0.901
validation
cohort,
highlighted
its
potential
clinical
utility.
However,
we
several
methodological
limitations,
including
excluding
genomic
markers,
biases
from
retrospective
design,
limited
generalizability
due
single-center
study,
variability
image
interpretation.
We
propose
further
investigation
into
integrating
multi-omic
data,
conducting
larger
multicenter
studies,
utilizing
advanced
techniques.
Additionally,
importance
interdisciplinary
collaboration
improve
development
advocate
for
cost-effectiveness
analyses
facilitate
integration.
Overall,
this
may
early
detection
management
MLM
RC
patients,
with
promising
avenues
future
exploration.
Ongoing
research
domain
can
potentially
outcomes
quality
care
Advances
in
molecular
testing
and
precision
oncology
have
transformed
the
clinical
management
of
lung
cancer,
especially
non-small
cell
enhancing
diagnosis,
treatment,
outcomes.
Practical
guidelines
offer
insights
into
selecting
appropriate
biomarkers
assays,
emphasizing
importance
comprehensive
testing.
However,
real-world
data
reveal
underutilization
biomarker
consequently
targeted
therapies.
Molecular
often
occurs
late
diagnosis
or
not
at
all
practice,
leading
to
delayed
inadequate
treatment.
Enhancing
requires
adherence
best
practices
by
health
care
professionals
involved,
which
can
ultimately
improve
cancer
patient
The
future
for
will
likely
involve
a
more
personalized
approach,
starting
increasingly
from
earlier
disease
settings,
with
novel
complex
therapies,
immunotherapies,
combination
regimens,
relying
on
liquid
biopsies,
muti-detection
advanced
genomic
technologies
integration,
artificial
intelligence
as
central
orchestrator.
This
review
presents
currently
known
actionable
mutations
new
upcoming
ones
that
are
enter
practice
soon
provides
an
overview
established
emerging
concepts
methodologies.
Challenges
discussed
recommendations
made
relevant
today,
continue
be
future,
other
types
too.
Cancer and Metastasis Reviews,
Год журнала:
2025,
Номер
44(2)
Опубликована: Апрель 22, 2025
Tumor
heterogeneity,
characterized
by
the
presence
of
diverse
cell
populations
within
a
tumor,
is
key
feature
complex
nature
cancer.
This
diversity
arises
from
emergence
cells
with
varying
genomic,
epigenetic,
transcriptomic,
and
phenotypic
profiles
over
course
disease.
Host
factors
tumor
microenvironment
play
crucial
roles
in
driving
both
inter-patient
intra-patient
heterogeneity.
These
can
exhibit
different
behaviors,
such
as
rates
proliferation,
responses
to
treatment,
potential
for
metastasis.
Both
heterogeneity
pose
significant
challenges
cancer
therapeutics
management.
In
retinoblastoma,
while
at
clinical
presentation
level
has
been
recognized
some
time,
recent
attention
shifted
towards
understanding
underlying
cellular
review
primarily
focuses
on
retinoblastoma
its
implications
therapeutic
strategies
disease
management,
emphasizing
need
further
research
exploration
this
challenging
area.
The Journal of Liquid Biopsy,
Год журнала:
2025,
Номер
8, С. 100297 - 100297
Опубликована: Апрель 29, 2025
Liquid
biopsy
offers
a
minimally
invasive
method
for
detecting
and
monitoring
cancer,
with
key
biomarkers
including
circulating
tumor
cells
(CTCs),
cell-free
DNA
(cfDNA),
extracellular
vesicles
(EVs).
Among
these,
CTCs
provide
dynamic
insights
into
heterogeneity,
metastatic
potential,
therapeutic
resistance
through
molecular
profiling
single-cell
analysis.
This
review
examines
recent
advancements
in
technologies
such
as
microfluidics,
nanotechnology,
next-generation
sequencing
(NGS),
which
have
improved
the
accuracy
clinical
use
of
CTC
detection.
A
comparative
analysis
liquid
techniques
highlights
strengths
limitations
platforms,
NGS,
digital
PCR
(ddPCR),
quantitative
(qPCR),
providing
diagnostic
significance.
Combining
genomic,
transcriptomic,
proteomic
analyses
artificial
intelligence
(AI)
tools
has
enhanced
supports
personalized
treatment
decisions
precision
oncology.
Despite
notable
progress,
issues
like
assay
standardization,
sample
variability,
regulatory
complexity,
data
integration
still
limit
widespread
use.
Future
directions
emphasize
interdisciplinary
innovation,
validation,
robust
bioinformatics
frameworks
to
facilitate
seamless
incorporation
CTC-based
standard
oncology
practice.
Overcoming
these
challenges
may
allow
become
tool
early
cancer
detection,
ongoing
monitoring,
individualized
treatment.
Nucleic Acids Research,
Год журнала:
2023,
Номер
52(D1), С. D607 - D621
Опубликована: Сен. 27, 2023
Abstract
Liquid
biopsy
has
emerged
as
a
promising
non-invasive
approach
for
detecting,
monitoring
diseases,
and
predicting
their
recurrence.
However,
the
effective
utilization
of
liquid
data
to
identify
reliable
biomarkers
various
cancers
other
diseases
requires
further
exploration.
Here,
we
present
cfOmics,
web-accessible
database
(https://cfomics.ncRNAlab.org/)
that
integrates
comprehensive
multi-omics
data,
including
cfDNA,
cfRNA
based
on
next-generation
sequencing,
proteome,
metabolome
mass-spectrometry
data.
As
first
in
field,
cfOmics
encompasses
total
17
distinct
types
13
specimen
variations
across
69
disease
conditions,
with
collection
11345
samples.
Moreover,
includes
reported
potential
reference.
To
facilitate
analysis
visualization
offers
powerful
functionalities
its
users.
These
include
browsing,
profile
visualization,
Integrative
Genomic
Viewer,
correlation
analysis,
all
centered
around
genes,
microbes,
or
end-motifs.
The
primary
objective
is
assist
researchers
field
by
providing
This
enables
them
explore
cell-free
extract
profound
insights
can
significantly
impact
diagnosis,
treatment
monitoring,
management.
Oral Diseases,
Год журнала:
2024,
Номер
30(6), С. 3962 - 3965
Опубликована: Янв. 2, 2024
The
authors
have
no
conflict
of
interest
to
declare.
data
that
support
the
findings
this
study
are
available
from
corresponding
author
upon
reasonable
request.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(14), С. 11792 - 11792
Опубликована: Июль 22, 2023
The
most
promising
method
for
monitoring
patients
with
minimal
morbidity
is
the
detection
of
circulating
melanoma
cells
(CMCs).
We
have
shown
that
CD45−CD146+ABCB5+
CMCs
identify
a
rare
primitive
stem/mesenchymal
population
associated
disease
progression.
epithelial-to-mesenchymal
transition
(EMT)
confers
cancer
hybrid
epithelial/mesenchymal
phenotype
promoting
metastatization.
Thus,
we
investigated
potential
clinical
value
EMT
gene
signature
these
CMCs.
A
reliable
quantitative
real-time
polymerase
chain
reaction
(qRT-PCR)
protocol
was
settled
up
using
tumor
cell
lines
RNA
dilutions.
Afterwards,
immune-magnetically
isolated
from
advanced
patients,
at
onset
and
first
checkpoint
(following
immune
or
targeted
therapy),
were
tested
level
hallmarks
transcription
factor
genes.
Despite
small
cohort
obtained
results.
Indeed,
observed
deep
rewiring
genes:
in
particular
found
correlated
patients’
outcomes.
In
conclusion,
established
qRT-PCR
high
sensitivity
specificity
to
characterize
expression
To
our
knowledge,
this
evidence
demonstrating
impact
therapies
on
hallmark
expressions
patients.
